Atika Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Atika Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-47,000	Closed	-$3.21M	–	124
2021 Q1	$3.21M	Sell	47,000 -96,000	-67%	-$7.76M	0.28%	80
2020 Q4	$12.3M	Buy	143,000 +14,500	+11%	+$1.23M	0.96%	47
2020 Q3	$8.35M	Sell	128,500 -17,000	-12%	-$1.11M	0.68%	50
2020 Q2	$10.6M	Buy	145,500 +71,500	+97%	+$3.81M	1.37%	23
2020 Q1	$2.52M	Sell	74,000 -11,000	-13%	-$503K	0.48%	58
2019 Q4	$4.63M	Buy	85,000 +9,000	+12%	+$446K	0.89%	53
2019 Q3	$3.17M	Sell	76,000 -36,893	-33%	-$1.56M	0.67%	52
2019 Q2	$4.94M	Buy	112,893 +41,893	+59%	+$2.36M	0.97%	43
2019 Q1	$3.65M	Buy	+71,000	New	+$3.07M	0.74%	52

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Atika Capital Management's BHVN Position: Q2 2021 in Review

Atika Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2021, closing a stake of 47,000 shares — an estimated $3.21M sold.

Atika Capital Management first reported a position in BHVN in Q1 2019 and held it in 9 quarters. The position peaked at $12.3M in Q4 2020. 223 funds tracked by Wall St. Rank hold BHVN as of Q2 2021.

Atika Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2021 after selling out during the quarter.
Atika Capital Management sold 47,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2021, an estimated $3.21M.
Atika Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 9 quarters.
Atika Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $12.3M in Q4 2020.
223 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2021.

Based on Atika Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.